A gene coding for human growth hormone, which consists of 192 amino acids, was chemically synthesized.
amino acids and methionine, was totally synthesized by chemical means, using amino acid codons most frequently appearing in Escherichia coli (11) (12) (13) (Fig. 1 ). To establish a general procedure for efficient expression of genes for relatively large peptides, hGH was thought to be a suitable target. Use of the synthetic gene will provide sufficient sites for restriction enzymes, which should be useful in mutations of genes for replacement of protein domains. Rapid synthesis of 78 gene fragments of 7-26 bases was carried out, followed by sequential ligation to construct the gene of 584 base pairs (bp). This is the longest gene so far synthesized chemically. Separately, a modified trp promoter was constructed that allows expression of any synthetic genes with an initiation codon placed downstream of it. A recombinant plasmid carrying the promoter and the hGH gene produced the hormone in E. coli at a high level. The induced polypeptide was indistinguishable from the natural hGH in several features. The purified hormone was as active as the natural growth hormone in biological tests (14) .
MATERIALS AND METHODS
Deoxyoligonucleotides. Deoxyoligonucleotides with a chain length of [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] bases were synthesized by the phosphotriester solid-phase method, using 1% cross-linked polystyrene (15) as the support. Altogether 78 chains were prepared by addition of dinucleotide blocks to the nucleosides linked through a 3'-succinyl group to the resin. Tetranucleotide blocks prepared by condensation of dimers in the liquid phase were used for the synthesis of the 25-mer (A-UO; Fig.  1 ). Sixteen dinucleotide blocks were prepared with mesitylenesulfonyl-3-nitro-triazolide (16) by methods essentially as reported (17) and purified mostly by reversed-phase chromatography (18) under conditions described (19, 20) . A typical synthesis of a 15-mer started with treatment of the 5'-dimethoxytritylated nucleoside resin (5 ,umol) with benzenesulfonic acid (17) (2%; 2 ml) for 1 min twice in a small vessel with a sintered glass plate and a stopcock at the bottom. In the case of deoxyadenosine resin, either zinc bromide (21) or 3% trichloroacetic acid (22) was used. A dimer (20 ,umol) was treated with MSNT (70 ,umol) in pyridine (200-300 Al) at 40'C for 20 min. The resin was treated with acetic anhydride (0.2 ml) in 4-dimethylaminopyridine-pyridine (0.1 M; 1.8 ml) for 3 min. The product was deblocked with 1,1,3,3-tetramethylguanidium 2-pyridinealdoximate in dioxane-H20 (0.5 M, 90% dioxane) (16) at 300C overnight and with concentrated ammonia at 550C for 5 hr. The dimethoxytritylated 15-mer was separated on a column (0.7 x 6 cm) of C-18 silica gel (Waters; 35-100 pum) with a gradient of acetonitrile (10%to-35%; total, 200 ml) in 0.05 M ammonium acetate and treated with 80% acetic acid. The product was applied to a column (0.7 x 21 cm) of DEAE-Toyopearl 650S (Toyosoda) with a gradient of sodium chloride (0.1-0.3 M; total, 200 ml) in 7 M urea/20 mM Tris HCl, pH 7.5. The 15-mer was checked by high-pressure liquid chromatography (HPLC) on C-18 silica gel (Toyosoda, TSK-410 AK) and ion exchange (Toyosoda, TSK gel IEX540K). Impurities were removed by HPLC, and the purity and sequence were confirmed by mobility-shift analysis (23 Fig. 2 , and the duplex (0.5 pmol) was joined to the Cla I/Sal I sites of the expression vector pCT-1 to yield plasmid phGH-1 (Fig. 3) .
To improve the efficiency of its expression, the promoter region of phGH-1 was modified as follows. First, the region between the Hpa I site at -11 and the Cla I site at + 157 was eliminated to remove the attenuator (trpL) along with the SD sequence of trpE. These were replaced by a synthetic oligonucleotide consisting of either 33, 35, or 37 nucleotide pairs, each carrying a SD sequence (A-A-G-G) and with appropriate termini. The resulting plasmids, pGH-L9, pGH-L11, and pGH-L13, carry 9, 11, or 13 bases upstream of the initiation codon (ATG) of the hGH gene (Fig. 3) Immunochemical. Biological activity of the induced product, which was fractionated by chromatography on DEAE-cellulose (Whatman DE-52), was tested on hypophysectomized rats (14) .
RESULTS
Synthesis of hGH Gene. The amino acid sequence of hGH and the synthetic gene fragments for methionyl hGH are shown in Fig. 1 . The gene was divided into three parts-the amino terminal (A), the middle part (B), and the carboxyl terminal (C). Amino acid codons used in the present gene were chosen mainly from those found in a gene for elongation factor Tu (tufA) of E. coli (13) . Homologous or complementary sequences were sought with a microcomputer, and codons were altered to avoid mismatches in duplex alignments. The amino acid codons used in the present synthesis are shown in Table 1 , together with those found in a human gene (27) . As indicated in Fig. 1 , sequences for the restriction enzymes Cla I, Sal I, Hinf Bgl II were incorporated to clone the fragments into the vector and to facilitate modifications. A single cleavage sequence for each of these enzymes was designed. The methionine codon and the termination codons were also added at the appropriate positions. Dinucleotide blocks were mainly used, except for the synthesis of AUO (25-mer), where tetramer blocks were used. As expected, the use of larger oligonucleotides as condensing units was found to be advantageous in obtaining the pure product, although synthesis of protected tetranucleotides was time consuming. All fragments were finally examined by HPLC on reversed-phase and mobility shift analyses (23) .
Construction of Plasmids Carrying the hGH Gene Under Control of the trp Promoter. Enzymatic ligation of the 78 chemically synthesized oligonucleotides was carried out by joining [5] [6] [7] [8] [9] [10] pieces in the first step. The subfragments thus obtained were further ligated to yield 415-bp (A+B segment: amino-terminus portion) and 176-bp (C segment: carboxylterminus portion) polynucleotides. The C-segment was integrated into a plasmid, replacing the region between the Cla I and Sal I sites of pCT1 (Fig. 2) to generate phGHC-1. After amplification, the 165-bp C segment was extracted by digestion with Bgl II and Sal I, and ligated to the 415-bp A+B segment to yield the whole hGH gene, which was inserted into the plasmid pCT1 as shown in Fig. 2 . The resulting plasmid phGH-1 carries the 584-bp synthetic gene under the control of the trp promoter and the SD sequence for trpE.
The attenuator was next removed from phGH-1, and the synthetic gene was placed at different distances from the trpL SD sequence A-A-G-G (Fig. 3) . Plasmids 
Construction of plasmids containing the synthetic hGH gene. pCT-1 and phGH-1 were obtained as described in Materials and Methods. Dotted lines are identical to the sequence of the trp operon (25) . To replace Hpa I/Cla I fragments, DNA duplexes of 33, 35, and 37 bp were prepared by joining four synthetic fragments in each duplex.
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Proc. NatL Acad ScL USA 81 (1984) I Table 1 Transformation and Expression of the Gene in E. coli. The synthetic gene inserted in the plasmid, and the modified regions around the SD sequences were identified by sequence analyses (28) . The plasmids were used to transform E. coli HB1O1 (29) , and the transformants were examined for expression of the hGH gene upon induction by 3-indolylacrylic acid at eariy logarithmic phase (24) . The cells were collected after 23 hr of induction, lysed, and the proteins were analyzed by electrophoresis in reducing NaDodSO4/ polyacrylamide gels (30) . The results are shown in Fig. 4 . E.
coli cells carrying pGH-L9 synthesized the product most efficiently. From radioimmunoassay, the yield of hGH was estimated to be 169 ji~g per ml of culture medium, or 2.9 x 106 molecules per cell. As shown in Table 2 , pGH-L8, pGH-L11, and pGH-L13 also yielded hGH at a higher level upon induction compared to phGH-1. E. coli cells carrying these plasmids had to be treated with 6 M guanidine hydrochloride (31) . The Analysis of the Induced Protein. The molecular weight of the product was estimated from the mobility in reducing gel electrophoresis as 21,000 (Fig. 4) . The amino terminus of the product was analyzed by Edman degradation and found to be methionine.
Immunological properties of the induced peptide were examined by two procedures. Table 2 summarizes the results of radioimmunoassay of hGH in extracts from bacteria containing expression plasmids by the solid method (26) .
Biological activity of the induced peptide was examined in hypophysectomized rats. In tests of weight increase and increase in the width of the proximal epiphyseal cartilage of the tibia, the synthesized hGH showed equal activity to that of the natural growth hormone.
DISCUSSION
hGH is known to be responsible for the growth of bones and is currently used for treatment of hypopituitary. dwarfism (10) . Other amino-terminal gene, and expressed in E. coli under the control of lac (26) or tac (32, 33) promoters. It was shown that pGH-L9, which carried the SD sequence of trpL 9 bases upstream from the initiation codon, produced methionyl hGH most efficiently. The production of methionyl hGH was about 5 times that of phGH-1, which contained the attenuator and the SD sequence of trpE. This efficiency is also 10 times higher than that reported previously (32, 33) . The distance of the synthetic gene from the trpL SD sequence A-A-G-G seemed to affect the efficiency of the expression. As shown in Table 2 , the efficiency for pGH-L9 is significantly higher than that for pGH-L8, pGH-L11, or pGH-L13.
The usage of amino acid codons most frequently appearing in E. coli should favor the expression, because it was shown that there was a good correlation between the frequency of codon usage and the amount of corresponding tRNAs.
Expression vectors used in this study can be applied to any genes having proper sequences for restriction enzymes and the initiation and termination codons.
Any proteins of -200 amino acids may be prepared by the recombinant DNA technique in bacteria by use of chemically synthesized genes. Site-directed mutations of amino acids or domains can be designed by replacing nucleotides in the corresponding region of the gene fragments. The present hGH gene was also designed to facilitate modification of hGH by replacement of deoxyoligonucleotides.
